Literature DB >> 4270384

BCG vaccination of children against leprosy: seven-year findings of the controlled WHO trial in Burma.

L M Bechelli, P G Garbajosa, M M Gyi, K Uemura, T Sundaresan, V Martínez Domínguez, M Matejka, C Tamondong, R Quagliato, V Engler, M Altmann.   

Abstract

A controlled study of the efficacy of BCG vaccination for the prevention of leprosy began in Burma at the end of August 1964. This paper presents the findings after 7 years-i.e., the results of 6 annual follow-up examinations up to the end of June 1971. The incidence rate in BCG-vaccinated children 0-4 years of age at intake was lower than that in children in the control group. The protection conferred by BCG was relatively low (44%) and applied only to early cases of leprosy, the great majority tuberculoid cases. BCG vaccination did not protect household contacts or children 5-14 years of age who were not exposed in the household. This reduction must be interpreted in the light of several factors: form of leprosy, bacterial status, lepromin reactivity, evolution of cases, and level of endemicity. Consequently it does not seem probable that the reduction in incidence would substantially affect the pattern or trend of the disease in an area similar to that where the study is being carried out; the probability would be much lower if not nil in regions of relatively low endemicity (1-2 per 1 000 or less).

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4270384      PMCID: PMC2481055     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  Self-healing, or abortive, and residual forms of childhood leprosy and their probable significance.

Authors:  C B LARA; J O NOLASCO
Journal:  Int J Lepr       Date:  1956 Jul-Sep

2.  [Correlation between the results of the clinical reading & the histopathological examination of Mitsuda reaction].

Authors:  L M BECHELLI; P R DE SOUZA; R QUAGLIATO
Journal:  Rev Bras Leprol       Date:  1957 Jan-Mar

3.  BCG vaccination of children against leprosy. Preliminary findings of the WHO-controlled trial in Burma up to January 1970.

Authors:  L M Bechelli; P G Garbajosa; M M Gyi; K Uemura; V Engler; V M Dominguez; T Sundaresan; R Quagliato; M Matejka
Journal:  Int J Lepr Other Mycobact Dis       Date:  1971 Apr-Jun

4.  BCG vaccination of children against leprosy. Preliminary findings of the WHO-controlled trial in Burma.

Authors:  L M Bechelli; G Garbajosa; K Uemura; V Engler; V Martínez Domínguez; L Paredes; T Sundaresan; G Koch; M Matejka
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

  4 in total
  15 in total

1.  BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea, 1963-79.

Authors:  A Bagshawe; G C Scott; D A Russell; S C Wigley; A Merianos; G Berry
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

2.  Human T-cell clones with reactivity to Mycobacterium leprae as tools for the characterization of potential vaccines against leprosy.

Authors:  F Emmrich; S H Kaufmann
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

3.  BCG-induced suppressor T cells optimal conditions for in vitro induction and mode of action.

Authors:  A S Mustafa; T Godal
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

4.  BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma.

Authors:  K Lwin; T Sundaresan; M M Gyi; L M Bechelli; C Tamondong; P G Garbajosa; H Sansarricq; S K Noordeen
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

5.  BCG vaccination of children against leprosy: nine-year findings of the controlled WHO trial in Burma.

Authors:  L M Bechelli; K Lwin; P Gallego Garbajosa; K Uemura; T Sundaresan; C Tamondong; M Matejka; H Sansarricq; J Walter
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

6.  In vitro lymphocyte response to purified protein derivative, BCG and Mycobacterium leprae in a population not exposed to leprosy.

Authors:  O Closs
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

7.  In vitro induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation.

Authors:  A S Mustafa; T Godal
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

8.  Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts.

Authors:  Isabela M B Goulart; Dulcinéa O Bernardes Souza; Carolina R Marques; Vânia L Pimenta; Maria A Gonçalves; Luiz R Goulart
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

9.  Epidemiological information on leprosy in the Singu area of Upper Burma.

Authors:  V Martínez Domínguez; P Gallego Garbajosa; M Mg Gyi; C T Tamondong; T Sundaresan; L M Bechelli; K Lwin; H Sansarricq; J Walter; F M Noussitou
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

10.  BCG vaccination of children against leprosy in Uganda: final results.

Authors:  S J Stanley; C Howland; M M Stone; I Sutherland
Journal:  J Hyg (Lond)       Date:  1981-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.